Check for updates

OPEN ACCESS

EDITED BY Gianvito Lanave, University of Bari Aldo Moro, Italy

REVIEWED BY Adriana Delfraro, University of the Republic, Uruguay Arunachalam Ramaiah, Georgia Department of Public Health, United States

*CORRESPONDENCE Lester J. Perez ⊠ lester.perez@abbott.com Jorge E. Osorio ⊠ jorge.osorio@wisc.edu

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 19 December 2024 ACCEPTED 20 March 2025 PUBLISHED 07 April 2025

CITATION

Perez LJ, Perez-Restrepo LS, Ciuoderis K, Usuga J, Moreno I, Vargas V, Arévalo-Arbelaez AJ, Berg MG, Cloherty GA, Hernández-Ortiz JP and Osorio JE (2025) Emergence, persistence, and positive selection of yellow fever virus in Colombia. *Front. Microbiol.* 16:1548556. doi: 10.3389/fmicb.2025.1548556

COPYRIGHT

© 2025 Perez, Perez-Restrepo, Ciuoderis, Usuga, Moreno, Vargas, Arévalo-Arbelaez, Berg, Cloherty, Hernández-Ortiz and Osorio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Emergence, persistence, and positive selection of yellow fever virus in Colombia

Lester J. Perez^{1,2*†}, Laura S. Perez-Restrepo^{2,3†}, Karl Ciuoderis^{2,3}, Jaime Usuga^{2,3}, Isabel Moreno^{2,3}, Vanessa Vargas^{2,3}, Angela J. Arévalo-Arbelaez^{2,3}, Michael G. Berg^{1,2}, Gavin A. Cloherty^{1,2}, Juan Pablo Hernández-Ortiz^{3,4} and Jorge E. Osorio^{2,3,5,6*}

¹Infectious Diseases Research, Abbott Diagnostics, Chicago, IL, United States, ²Abbott Pandemic Defense Coalition, Chicago, IL, United States, ³GHI One Health Colombia, Universidad Nacional de Colombia, Medellín, Colombia, ⁴Faculty of Life Sciences, Universidad Nacional de Colombia, Medellín, Colombia, ⁵Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, United States, ⁶Global Health Institute, University of Wisconsin, Madison, WI, United States

Yellow fever virus (YFV) is an arbovirus that causes acute febrile illness (AFI), in tropical areas of South America and Africa. Through a 2020–2023 AFI study in Leticia, Colombia, leveraging metagenomic next-generation sequencing (mNGS), we identified and isolated YFV (LET1450). Phylogenetic analysis showed this strain belongs to South American genotype II (SamII), linked to Peruvian and Bolivian sequences emerging around 1989. Phylodynamic analysis indicates these strains, with a unique genetic makeup, could have reduced vaccine susceptibility, and due to positive Darwinian selection have an enhanced adaptive capacity. Antigenic analysis identified additional immune-evasive traits and this strain's potential for wider Latin American spread. Phylogeographic reconstruction demonstrated the persistence of YFV in Colombia is not due to repeated external introductions, but results from continuous, cryptic internal circulation. This study highlights the crucial role of mNGS in monitoring emerging strains and underscores the need for genomic surveillance of YFV and other arboviral infections.

KEYWORDS

yellow fever virus, acute febrile illness, deimmunization, positive selection, phylodynamic, whole genome sequencing

Highlights

Despite decades of control efforts, vaccination coverage for Yellow Fever Virus (YFV) is variable and YFV remains a significant cause of acute febrile illness (AFI) in tropical regions of South America and Africa. A potential vaccine-escape strain of YFV belonging to the poorly characterized South American genotype II was identified in a febrile patient by next generation sequencing. The identification of specific adaptive mutations suggests the virus' capacity to evolve will enable its expansion beyond current geographic boundaries. Recognition of YFV's continuous circulation in the Amazon region and the emergence of resistance should heighten awareness and inform public health measures.

10.3389/fmicb.2025.1548556

1 Introduction

Yellow fever (YF) is an acute, vector-borne zoonotic illness endemic to tropical areas in America and Africa. This disease is caused by yellow fever virus (YFV) and it is transmitted by several mosquito species within the Aedes, Sabhetes, and Haemogogous genera (Cardoso et al., 2010). YFV belongs to the Flaviviridae family that contains other viruses of clinical importance such as dengue virus (DENV), Zika virus (ZIKV), West Nile virus (WNV), and Japanese encephalitis virus (JEV) (Gardner and Ryman, 2010). Most infections with YFV are asymptomatic or present as selflimiting, non-specific febrile illness, but occasionally, patients progress to a more severe disease phase resulting in hepatorenal failure and death (Paules and Fauci, 2017). Yellow fever affects more than 200,000 people per year worldwide, with at least 60,000 deaths annually (Malik et al., 2023). Although there is currently no specific anti-viral drug for YF available, a live attenuated vaccine (17D) has been effectively used since the 1930s to prevent disease (Kieffer et al., 2019).

Sporadic outbreaks of YF have been reported in the southeastern and northeastern areas of Colombia, including the Amazon region which represents about 30% of the landmass (Instituto Nacional de S, 2023). During the past 20 years, at least 215 cases of sylvatic YF cases were confirmed primarily in departments located within or bordering the Amazon region (Vichada, Guaviare, Meta, Caquetá, Vaupés, Amazonas). The most recent case reported occurred in Leticia (Amazonas) in May, 2023 (Instituto Nacional de S, 2023). Vaccination provides effective, long-lasting immunity and has served as the main prevention strategy for YF control in Colombia (Kieffer et al., 2019). However, with the recent COVID-19 pandemic, vaccination programs were abruptly halted (World Health Organization, 2023a). The resulting low herd immunity, along with massive human migration, have impacted the dynamics of virus transmission. Climatic and environmental factors may also be increasing the likelihood of new YFV outbreaks (Kieffer et al., 2019; Instituto Nacional de S, yellow fever virus 2023; Pan American Health Organization, 2023).

Beginning in December 2020, a hospital-based fever surveillance study has been conducted in four regions of Colombia, part of an ongoing virus discovery research program of the Abbott Pandemic Defense Coalition (APDC) (Averhoff et al., 2022). This program aims to better understand the causes of acute febrile syndrome of unknown origin in hot-spot areas where vector-borne diseases are transmitted. Here we describe the detection, isolation, and genetic characterization of YFV from a febrile patient in the Amazon River basin of Colombia.

2 Results

Acute febrile illness (AFI) surveillance was carried out in four different regions of Colombia between December 2020 and April 2023. Acute-phase sera were collected from 4,746 individuals aged 5 to 96 years, of which 54.3% were females (2,575/4746). Combined RT-PCR and antigen rapid diagnostic testing resulted in detection of dengue (11.7%, 555/4746), malaria (7.8%, 369/4746), COVID-19 (1.9%, 93/4746), Influenza (0.3%, 13/4746), and Zika cases (0.02%, 1/4746). However, after laboratory screening, 53.3% (2,528/4746) of the AFI cases remained of unknown origin (Figure 1A). Of these,

28.8% (727/2528) were from Leticia in the Amazon region. For this study, 7.2% (52/727) of the unknown samples from Leticia were randomly selected for mNGS.

A full genome of YFV was assembled from a 23-year-old indigenous male patient (LET-1450) residing in a semi-urban area of Leticia (Figure 1B). The patient experienced 2 days of fever, vomiting and chills and presented with headache and body/muscle pain. Based on echography, findings indicated enlarged liver, pancreas, spleen, and kidney. Urinalysis and the subject's additional lab results are described in Supplementary Table S1. A differential diagnosis of leptospirosis was given based on a preliminary diagnosis of urinary tract infection. The subject was treated with cephalosporine, antipyretic, antiemetic, and sodium chloride and was kept overnight for observation. The next day the subject exhibited jaundice and persistent abdominal pain on the left side. Liver function test resulted in increased values as follows: aspartate transaminase 3,260 U/L (reference range 8 to 48 U/L), alanine transaminase 2,280 U/L (reference range 7 to 55 U/L), total bilirubin 2.67 mg/dL (reference range 0.1 to 1.2 mg/dL), and direct bilirubin 2 mg/dL (reference range 0.1 to 0.3 mg/dL). According to the epidemiological survey, the patient indicated prior vaccination against yellow fever virus. Despite these symptoms, the subject refused hospitalization and was lost to follow up.

YFV was successfully isolated following inoculation of infected serum onto Vero cell monolayers. Phylogenetic analysis of all available YFV reference strains delineated seven previously established genotypes (Figure 1C). The LET1450/Colombia/2023 strain clustered with Bolivian sequences, together forming a distinct monophyletic clade within the South American genotype II (SamII), rooted with a Brazilian sequence from 1983 (*zoomed section* Figure 1C). The notably longer branch for the Colombian sequence suggests a prolonged circulation of this strain within Colombia or its vicinity before detection.

To determine the evolutionary timeline for the introduction of the SamII YFV lineage into Colombia, we conducted a temporal analysis that traced its emergence and diversification (Figure 2A). We estimated the time to the most recent common ancestor (tMRCA) of YFV overall to be around 1,671 (95% HPD [1504-1714]), aligning closely with the first historically documented case of YF in 1648 (Staples and Monath, 2008). Our analysis further revealed significant evolutionary landmarks, including the diversification of the Asian (A), Eastern Asian (EA), and Central Eastern Asian genotypes around 1812. Additionally, the emergences of the West African (WA), West African II, and South American genotypes were traced back to approximately 1883, and the rise of the South American II lineage, the most recent, emerged around 1971. The ancestor of the Colombian strain was estimated to have arisen around 1989. The Skygrid plot summarizing the entire YFV dataset (Figure 2B) indicates that viral genetic diversity remained stable for over two centuries but experienced a sharp decline coinciding with the global introduction of YFV vaccination efforts that began in ~1950's (Frierson, 2010). The analysis indeed highlights the vaccine's effectiveness in reducing transmission and disease. However, we observed a slight uptick in genetic diversity between 1978 and 1985 (Figure 2B). This period corresponds with the further diversification of the South American genotype II (SamII) and the formation of the Peru, Bolivia, and Colombia clusters. These findings suggest that their emergence may have been linked to a positive selection event and/or attributed to an inherent immune evasion characteristic.



The Single Likelihood Ancestor Counting (SLAC) method was deployed to describe the complex landscape of positive nucleotide selection events occurring across the YFV genome (Figure 3A). In parallel, we assessed diversification at the codon level, together with Shannon entropy mapping, to visualize amino acid changes. This combined strategy revealed regions characterized by high levels of diversity and indicative of positive selective pressure, but in general, most of the genome appeared to be under neutral selection or purifying selection (Figure 3A). This finding is consistent with the estimated evolutionary rate of YFV, which is 6.33×10^{-4} (95% HPD interval: 5.3×10^{-4} to 7.1×10^{-4}). Sites under positive Darwinian selection are

likely to herald the emergence of new viral strains. Hence, a branch-site analysis was performed to gain insight into the evolutionary dynamics giving rise to the SAmII genotype sequences from Peru, Bolivia, and Colombia. Results indicate that this cluster did emerge as a result of positive, episodic selection, with a statistically supported (p < 0.01) value for dN/dS = 2.51 (Supplementary Table S2; Figure 3B). From the branch-site analysis, the T1185V mutation, located at position 47 in the non-structural protein 2a (Ns2a), was flagged as instrumental in determining this outcome (Supplementary Table S2; Figure 3B). This same site was also identified as being under positive selection in our SLAC method analysis (Figure 3).



Having established that positive selection was driving the emergence of this cluster within the South American II genotype, we next examined these strains' potential for immune evasion with a site-specific positive selection analysis of the envelope (E) protein. To increase sensitivity compared to SLAC and minimize false positives, positive selection models were contrasted with neutral selection models, according to Perez et al. (Perez et al., 2022), to determine the action of pervasive selection. A variety of YFV genotypes, sampled over different periods, were included in the analysis (Alignment E protein available at https://github.com/LesterJP/YFV_Colombia). The results highlighted several sites under strong positive selection with omega values (dN/dS) > 14, confirmed by significant statistical support (p < 0.01) (Supplementary Tables S3, S4). Notably, 7 of the 12 positively selected sites in E were present in the SamII lineage (Supplementary Table S2; Figure 3C), with A343S found exclusively in the Peru/Bolivia/Colombia cluster. This mutation is situated in one of the exposed loops of domain III of the envelope protein responsible for receptor-mediated attachment (Figure 3C). To explore whether the positively selected sites identified in DIII of the envelope protein confer immune evasion capability, particularly to the vaccine,



complete coding region. The top panel shows the maps amino acid entropy rates with a cutoff value of 0.5 to underscore highly variable regions, alongside with the map of the premature and mature peptide of YFV along with the disparity between non-synonymous (dN) and synonymous (dS) rates (dN-dS). Codon-specific rates of dN and dS substitutions obtained from the Datamonkey web-server using the SLAC method are plotted. Specific sites (the region in the case of the E protein) identified as positively selected are highlighted in red. (**B**) Episodic selection analysis for the YFV SamII genotype is detailed, where diversification nodes were individually assessed as foreground branches. A node indicating episodic selection is identified by a ω 2 value greater than 1 when daughter branches were chosen as foreground. The specific site associated with this selection event is also presented (Supplementary Table S2). (**C**) A 3D representation of the E glycoprotein (PDB ID: 8ofn) shows the domains in distinct colors: Domain I (DI) in red, Domain II (DII) in yellow, and Domain III (DIII) in blue. Positively selected sites resulting from pervasive selection are indicated as spheres (Supplementary Tables S3, S4). Sites with no amino acid replacements in the SamII genotype are in gray, while those with replacements in SamII and other genotypes are in orange. A unique site exclusive to SamII strains is highlighted in gold. Positions are annotated according to the PDB structure numbering, and the corresponding amino acid replacements and genotypes are detailed. (**D**) Analysis of deimmunization effects induced by amino acid replacements at positively selected site exclusive to contemporary SamII strains (marked with red spheres), including the Colombian strain. Deimmunization scores (DS) are noted, alongside the impacts on each antigenic peptide.

we assessed their de-immunization potential using the approach previously described by Coronado et al. (2019). A de-immunization score (DS) of 3 indicates that the A343S replacement strongly contributes to a reduction in antigenicity (Supplementary Table S1; Figure 3D), as does the adjacent I344V mutation (DS = 3.0), a combination that potentially produces a synergistic effect. Neither the F305S replacement identified on the opposite face of the protein, nor the R3331K (absent in the SamII genotype) located at the proximal loop region, impact the antigenicity of their respective peptides (Figure 3D). While the identification of the A343S suggests this and other mutations may impart unique adaptive features in these regional variants, it will require *in vitro* neutralization assays to determine their impact on vaccine escaping capacity.

To determine the origins and global dissemination of YFV, we performed a discrete phylogeographic analysis. The topological structure produced from the Markov jump count plot was consistent with the genotypic evolution of the virus, tracing the root to Uganda and highlighting the role of Brazil and Senegal in its worldwide dispersion (Figure 4A; Supplementary Figure S1). Regarding Colombia, our analysis pinpointed two major importation events from Peru and Bolivia, with transmission back to Bolivia (Figure 4A). To determine the most likely origin of the initial introduction of the SamII genotype into Colombia, we employed the *TaxaMarkovJump* history reconstruction method (Lemey et al., 2021). This approach pointed to a 'jump' from Brazil to Peru, identifying Peru as the primary source of simultaneous introductions into Colombia and Bolivia (Figure 4B). Furthermore, the Markov jumps, as represented in Figure 4B by vertical lines, were originated from Peru and Bolivia and leading into Colombia, which indicates multiple YFV introductions from these neighbors.



To address the key question of whether the prevalence of YFV strains in Colombia results from repeated external introductions or from continuous and cryptic endemic circulation, we conducted a *post hoc* analysis derived from the entire reconstructed history of the Markov jump trees. The *PersistenceSummarizer* tool (Lemey et al., 2021) allowed us to examine the flow of viral strains within a unique lineage that originated from the same country. Our study period spanned from 1975, the ancestral time point (T_a), to 2023, the time of evaluation (T_e), and revealed that circulation dynamics within Colombia were largely driven internally. Specifically, the analysis showed that 77% of the virus circulating in Colombia originated from within Colombia itself. Only 22% traced back to Peru and a mere 1% was linked to Bolivia (Figure 4C). These findings demonstrate that the majority of YFV activity in Colombia is due to endemic persistence rather than external introductions.

3 Discussion

Acute Febrile Illness (AFI) is caused by a wide variety of pathogens but presents with high similar, non-specific symptoms. Clinicians commonly refer to a AFI as a fever of unknown origin without an initially obvious etiology or without localizing signs (Ryan, 2024). It is a major reason for seeking healthcare in low- and middle-income countries in the tropics (Feikin et al., 2011) and its diagnosis is one of the most challenging to make in clinical settings (Peeling and Fongwen, 2022). Malaria and dengue are the most common infections associated with AFI in the tropics (Wangdi et al., 2019). Various geographically restricted pathogens (e.g., Mayaro), as well as the globally prevalent causal agents of AFI (e.g., Chikungunya), also drive the epidemiology of fever across tropical regions (Prasad et al., 2015). However, a high proportion of AFI are inconclusive after routine diagnostic testing and therefore the relative importance of undetected pathogens causing AFI remains under-appreciated (Bottieau and Yansouni, 2018). For example, the burden of AFI caused by arboviruses such as Oropouche virus may be highly underestimated in some regions (Ciuoderis et al., 2022; Moreira et al., 2018). In this study, the subject suffering from YF had been given a diagnosis of suspected leptospirosis during the early stages of the disease. Thus, considering the barriers to accessing targeted laboratory testing in resource-limited healthcare settings, such as those in the Amazon region of Colombia, the early confirmation of YFV infection was

indeed challenging. Molecular tools, such as metagenomic sequencing, may help to fill this gap. Several research studies have demonstrated the utility of mNGS for pathogen discovery and surveillance of neglected diseases (Chen et al., 2023; Wright et al., 2022; Jerome et al., 2019). In this context, the Abbott Pandemic Defense Coalition (Averhoff et al., 2022) is a key initiative which is helping to reduce this gap in information, while also providing with local capacity building, resources and training for enhancing the detection of uncommon and novel pathogens causing AFI worldwide.

Since 1970, YF has re-emerged as a public health threat in several tropical regions of the world. The largest outbreak of the past five decades in the Americas took place in Brazil between 2016 and 2018, with transmission outside the Amazon region generating hundreds of deaths (de Oliveira et al., 2020). Recently, persistent YFV circulation and outbreaks were reported in Africa at locations with little or no underlying immunity or in areas with no history of YF vaccination (World Health Organization, 2023b). In Colombia, two sylvatic YF cases were confirmed during 2023, occurring in the Amazon region, out of the 44 suspect cases investigated in the country (Instituto Nacional de S, 2023). In our globally interconnected world, marked by extensive international travel and trade, awareness of YFV re-emergence in regions with no prior exposure or immunity is more pressing than ever before and highlights the challenge for global public health (de Oliveira et al., 2020).

The recent emergence of the South American II genotype and the Peruvian/Bolivian/Colombian lineage demonstrates the continuous evolution and regional diversification of YFV in the Americas. The demographic reconstruction, as depicted in the Skygrid plot, illustrated the decline in viral genetic diversity following the commencement of vaccination efforts. Amid the broader scientific controversy around the YFV vaccine, our study agreed with others and underscored its pivotal role in controlling YFV (Rosenstein et al., 2021; Juan-Giner and Hombach, 2024). The slight increase observed from 1978 to 1985, coinciding with the diversification of the SamII lineage, typifies the challenge of uniformly suppressing highly genetically variable lineages through vaccination (Rosenstein et al., 2021). The unique immune responses elicited by these diverse strains can lead to disparate vaccine efficacy across lineages, as evidenced by the breakthrough cases documented by Faria, et al in the recent YFV outbreak in Brazil (Faria et al., 2018). Seven individuals infected with the circulating Sam I genotype were previously vaccinated against YFV (Faria et al., 2018). It is important to note that the subject in this study reported being vaccinated against YFV, which suggests the possibility of a breakthrough mutant capable of evading vaccineinduced immunity.

Our temporal analysis, while focused on the SamII genotype in Colombia, also uncovered key events in the timeline of YFV evolutionary dynamics and global dispersal. Our estimated time to the most recent common ancestor (tMRCA) of YFV around 1,671 to the historical documentation of the first yellow fever case in 1648 not only affirms the reliability of the Bayesian analytical methods but reinforces the need for extensive datasets to anchor phylogenetic dating. The diversification of various Asian and African genotypes aligns with periods of increased global mobility, especially during the 19th century when major advancements in maritime technology enhanced oceanic travel and facilitated extensive human movement (Rodrigue, 2020). These developments, along with the growth of international trade and colonial expansion, played a pivotal role in human activity, significantly contributing to viral spread (Galbraith and Barrett, 2009). Ours is the first study to document this historical progression and illustrates that, selective pressures (e.g., vaccines) are still being exerted to which YFV adapts.

The identification of evolutionary forces at work is crucial to understanding the adaptive mechanisms deployed by emerging viral strains (Yu and Cheng, 2022). Our analysis indicated that while most of the YFV genome appears to be under neutral or purifying selection (Figure 3), there were certain regions exhibiting high diversity and subject to positive selection. Focusing on the Peru, Bolivia, and Colombia cluster, we observed positive episodic selection indicative of ongoing region-specific evolutionary adaptation, potentially attributed to mutations such as T1185V in the non-structural protein 2a and A343S in domain III of the envelope protein. The A343S mutation found exclusively in the Peru/Bolivia/Colombia cluster within the SamII genotype provides a unique adaptive feature that likely contributes to immune escape. Indeed, our de-immunization analysis revealed a notable reduction in antigenicity linked to this mutation. Moreover, the emergence of the I344V mutation also found in strains of the SamI genotype adds another layer of complexity, especially as it runs in parallel to an unprecedented outbreak in the extra-Amazonian regions which has surpassed the scale of the last 7 years (Giovanetti et al., 2022). These particular mutations highlight a significant evolutionary step in YFV, potentially impacting both the viral transmissibility and the efficacy of existing vaccines. Vaccine coverage has held steady around 80% but has dropped in recent years during the COVID-19 pandemic (Shet et al., 2022). This lapse provides another window of opportunity for YFV to adapt to decreased pressure.

The predominance of internally driven YFV circulation in Colombia (Figure 4), as revealed in our study, challenges the prevailing assumption of the virus' propagation mainly through external introductions. This shift in understanding calls for a reevaluation of current public health strategies, emphasizing the need for targeted interventions addressing endemic transmission within the country, as recently described in Giovanetti et al. (2023). Considering the complexity of viral dynamics in endemic regions, continuous, comprehensive surveillance systems coupled with reliable diagnostic methods are required to monitor the evolution and spread of YFV within national borders. Given the potential implications for vaccine strategy and virus control, further studies are needed, including in vitro cross-neutralization assays, as previously mentioned. Another potential limitation of our study, despite utilizing one of the largest datasets of YFV genomes to date in comparison with other studies (Faria et al., 2018; Giovanetti et al., 2023; Li, 2022), is the limited number of genomes available, specifically for the SamII genotype. This comparatively smaller dataset for SamII genotype may not fully capture the complete genetic diversity and evolutionary dynamics of this genotype, which again underscores the need for more surveillance and sequencing. While this manuscript was under review, a surge in yellow fever cases with a fatality rate of nearly 50% was reported in Colombia and Brazil. According to updates from the Pan American Health Organization (PAHO) and the World Health Organization (WHO), an outbreak in Tolima's mountainous region has, as of February 2025, led to at least 31 reported cases and 15 deaths. This alarming development underscores the continued public health threat posed by arboviral diseases and highlights the urgent need for coordinated surveillance and intervention efforts, like the APDC (Averhoff et al., 2022) and

other networks seeking to detect emerging threats and respond with needed diagnostics is a step in this direction.

4 Materials and methods

4.1 Ethics statement

This research was conducted in accordance with the principles outlined in the Declaration of Helsinki. All procedures involving human subjects were approved by the Ethics Committee of the Corporación Investigaciones Biológicas (CIB 10102022). Informed consent was obtained from all participants prior to their inclusion in the study. Procedures for Yellow Fever Virus isolation were conducted in the Biosafety Level 3 facility at the University of Wisconsin-Madison under the approved Biosafety protocol # B00000089. Any potential conflicts of interest have been disclosed and managed appropriately.

4.2 Patient cohort

A hospital-based fever surveillance study was carried out in four different regions of Colombia (Villavicencio, Acacias, Apartadó and Leticia), beginning in December 2020. Written informed consent was obtained from adults (18 years or older) and informed assent was obtained for children and adolescents (aged 17 years or below). Parent/guardian of minors (<18 years) also provided written consent on their behalf.

4.3 AFI case definitions, specimen collections and pre-screening

AFI was defined as a recent onset of fever (body temperature \geq 38.5°C at the time of consultation or self-reported history within the preceding 7 days) in the absence of an obvious focus of infection. In addition, definition of AFI also included association with non-specific symptoms such as headache, body rash, and muscle and joint pains. Venous blood samples were tested at the point-of-care using rapid diagnostic tests for dengue (SD Bioline Dengue Duo, Abbott) and malaria (SD Bioline Malaria Ag P.f/Pan, Abbott). Serum/plasma samples were stored at -80°C until transportation to a central lab (One Health Genomic Lab (Universidad Nacional de Colombia, Medellin) for further testing. Samples were tested at the central lab by molecular assays (reverse transcription RT-PCR and/or PCR) for detection of malaria, dengue (DENV), Zika (ZIKV), chikungunya (CHIKV), influenza (IV), and severe-acuterespiratory-syndrome-related coronavirus (SARS-CoV-2). Testing was conducted following protocols described elsewhere (Kamau et al., 2013; Waggoner et al., 2016; de-Paris et al., 2012; Corman et al., 2020). This work was reviewed and approved by the Ethics Committee of the Corporación Investigaciones Biológicas (CIB 10102022).

4.4 Virus isolation

The infected serum sample (50 μ L) was inoculated onto sub-confluent Vero cell monolayers (T-25 flask) and incubated at 37°C

with 5% CO_2 following the protocol previously described (Furtado et al., 2022). Cells were observed daily for cytopathic effects (CPE). After CPE were observed, cell culture supernatant was collected and evaluated for YFV by RT-PCR as described (Nunes et al., 2011). Molecular testing was conducted using the MiniAmp Plus thermal cycler (Applied Biosystems). Virus isolation was conducted in a Biosafety Level 3 facility at the University of Wisconsin-Madison (Biosafety protocol # B0000089).

4.5 Metagenomic next generation sequencing (mNGS)

Random-primed cDNA libraries derived from the serum specimens were prepared for mNGS following the protocol described elsewhere (Berg et al., 2020). Briefly, total nucleic acid was converted to cDNA by priming with random hexamers and oligo(dT) using Superscript III (SSRTIII) 1st Strand reagents (Life Technologies, Carlsbad, CA, USA), followed by 2nd strand synthesis with Sequenase V2.0 T7 DNA pol (Affymetrix, Santa Clara, CA, USA). The Nextera XT (Illumina, San Diego, CA) kit was used to create barcoded, metagenomic NGS libraries which were then purified with AxyPrep magnetic beads, quantified on both a Tape Station (Agilent Technologies, Santa Clara, CA) and Qubit fluorometer (ThermoFisher Scientific, Waltham, MA), pooled and diluted to 650 pM for loading. The NextSeq2000 (Illumina, California, USA) platform was used for sequencing and data were analyzed using an open-source cloud-based tool (Kalantar et al., 2020).

4.6 Genomic data collection, alignment and phylogenetic analysis

We retrieved all sequence of YFV available in Nextstrain repository¹ on December 13th, 2023. All downloaded sequences, were aligned together with the sequences obtained in the current study using the MAFFT software v7.453 (Rozewicki et al., 2019) with settings for a "localpair" option alignment. The obtained alignments were then utilized for maximum likelihood (ML) phylogenetic inference using IQ-TREE2 (Nguyen et al., 2015) as described in Perez et al. (Perez et al., 2022). Additionally, two different traits including genotypes, geographic location were mapped into the phylogeny using the ggtree R package (Yu et al., 2017).

4.7 Temporal and demographic Bayesian inference

To estimate the temporal emergence and evolutionary rate of YFV, we generated time-scaled phylogenies using BEAST 1.10.5 (Suchard et al., 2018), incorporating the BEAGLE 3 library (Ayres et al., 2019) to improve computational efficiency. The molecular clock parameters employed in our study were based on the framework established by Perez et al. (2023). For our phylogenetic analysis,

¹ https://github.com/ViennaRNA/YFVnext

we selected the SkyGrid tree prior model (Hill and Baele, 2019), which is particularly fitted for handling fluctuating population dynamics over time. Our analytical process involved 16 independent runs conducted on an AZURE cloud server. Each run sampled from Markov Chain Monte Carlo (MCMC) chains at intervals of 9×10⁸ generations, with a sampling frequency of every 9×10^5 generations. The convergence of these runs was carefully evaluated based on the effective sample size (ESS) of parameter estimates. We keep to the standardized threshold of ESS > 200 for reliable convergence, determined using Tracer 1.7 software (Rambaut et al., 2018). After a 10% burn-in, the runs were combined using the LogCombiner software (Drummond and Rambaut, 2007). For the phylogenetic representation, we constructed a Maximum Clade Credibility (MCC) tree using TreeAnnotator software. Additionally, we employed Tracer 1.7 software (Rambaut et al., 2018) for the SkyGrid reconstruction, which provided a detailed depiction of the demographic history of YFV.

4.8 Discrete phylogeographic analysis

To investigate the geographical spread of YFV and identify the origins of external introductions as well as the local emergence of strains in Colombia, we employed discrete trait phylogeographic inference (Lemey et al., 2020) as conducted in Perez et al. (2022). This method allows for a detailed analysis of the geographical distribution and migration patterns of the virus. For further insights, *post hoc* analyses were conducted to estimate MarkovJump transitions and evaluate the persistence of the YFV strain within Colombia. These analyses utilized advanced tools from the BEAST codebase, specifically the TaxaMarkovJumpHistoryAnalyzer, TreeMarkovJumpHistoryAnalyzer, and PersistenceSummarizer developed by Lemey et al. (2020), and available at BEAST GitHub Repository. Visualization of these complex data sets was achieved through a combination of specialized R packages, including MarkovJumpR and circlize and a custom Python scripts.

4.9 Positive selection analyses

To thoroughly investigate the influence of pervasive and episodic selection on the evolution of YFV strains, we adapted the methodology described elsewhere (Alfonso-Morales et al., 2015) and incorporated additional modifications as proposed by Orf et al. (2023). Our analysis was structured into three distinct phases. In the first phase, we assessed the genetic diversity of YFV. This involved analyzing the Shannon Entropy and evaluating positive selection across a broad dataset using the Single Likelihood Ancestor Counting (SLAC) (DataMonkey web application) (Weaver et al., 2018) method on the complete coding region of all 1,211 YFV strains in our dataset. Following this, we proceeded to a more focused analysis that included the analysis of episodic selection, specifically targeting the SamII strain of YFV. We utilized the time-stamped MCC tree derived from our temporal analysis of these strains as inputs for the CODEML program within the PAML v.4.9 software package (Yang, 2007). In this analysis we aimed to identify which of both lineages were under positive selection within the complete coding genome of the SamII strains. We conducted branch-site tests on predetermined branches, (foreground branches) and compared them against the background branches. The comparison utilized the alternative Model A and the null Model A1. For the statistic support of this analysis we performed branch-site Likelihood Ratio Tests (LRTs). The significance of the LRTs was determined by the chi-squared (χ 2) distribution of twice the log ML difference between the two models, with degrees of freedom corresponding to the difference in the number of parameters between the models. Detailed results of this analysis, including the statistical significance of episodic selection events, are presented in Supplementary Table S2. For the assessment of pervasive selection on the envelope protein of YFV, we carefully selected sequences from various genotypes, ensuring each had high-quality annotations of this region. These sequences were chosen based on their representation of different temporal epochs identified in our temporal analysis. From this refined dataset (Supplementary Figure S1), we constructed a new ML tree using the IQ-TREE software. This tree was then utilized as the input for the CODEML program within the PAML v.4.9 software suite, where we applied site models M2 and M8. To accurately identify sites under positive selection, we implemented the Bayes Empirical Bayes method, which calculates posterior probabilities for these sites. To minimize the likelihood of false positives, we conducted a comparative analysis between the models used for detecting positive selection pressure (M2 and M8) and those indicative of neutral evolutionary processes (M1 and M7), as detailed in Anisimova and Yang (2007). All identified sites exhibiting positive selection (Supplementary Tables S2, S3), were exactly mapped onto the sequence alignment. Subsequently, these sites were located on the 3D structure of the protein from the Protein Data Bank (PDB ID: 80fn). This process enabled us to pinpoint the specific genotypes of YFV that exhibited mutations at these select sites. This mapping not only highlighted the spatial distribution of these mutations on the protein structure but also provided insights into the genotypespecific evolutionary adaptations of YFV.

4.10 Deimmunization prediction

The deimmunization prediction analysis we conducted follows the methodology described by Coronado et al. (2019). This process involves using a computational tool as described by Dhanda et al. (2018), which first identifies immunodominant regions in proteins and then predicts amino acid substitutions that could yield non-immunogenic variants of these proteins. Additionally, the tool assesses if these substitutions in immunogenic peptides might alter immunogenic sites in adjacent peptides. Our specific focus was to evaluate the role of a uniquely positively selected site found in the Peruvian/Bolivian/Colombian strain clade of the YFV envelope protein, in contrast to other positively selected sites identified in different YFV genotypes. To this end, we utilized the online deimmunization tool available at IEDB Deimmunization Tool with default settings. For interpreting the outcomes of this analysis, we referred to the scoring guidelines provided on the same platform, which can be accessed at IEDB Deimmunization Help http://tools. iedb.org/deimmunization/help/. This approach allowed us to discern how specific mutations in the envelope protein might affect its immunogenicity, providing valuable insights into potential mechanisms of immune evasion by the virus.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article and its Supplementary materials. Raw data including the alignment of all the genomes used and metadata associated are available at https://github.com/LesterJP/YFV_Colombia (Table S5). The YFV sequence obtained from this study is available at Genbank under accession number PP477075. The dataset for this article is available in the NCBI Sequence Read Archive (SRA). It can be accessed from BioProject accession number PRJNA1086472 and NCBI accession: SAMN40377634; SRA: SRS20734849.

Ethics statement

The studies involving humans were approved by Ethics Committee of the Corporación Investigaciones Biológicas (CIB 10102022). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

LP: Conceptualization, Investigation, Methodology, Software, Visualization, Writing – original draft, Writing – review & editing. LP-R: Formal analysis, Investigation, Project administration, Resources, Writing – review & editing. KC: Data curation, Formal analysis, Visualization, Writing – review & editing. JU: Formal analysis, Software, Writing – review & editing. IM: Formal analysis, Resources, Writing – review & editing. IM: Formal analysis, Resources, Writing – review & editing. VV: Data curation, Resources, Writing – review & editing. AA-A: Formal analysis, Investigation, Writing – review & editing. MB: Conceptualization, Supervision, Visualization, Writing – original draft, Writing – review & editing. GC: Conceptualization, Supervision, Writing – review & editing. JH-O: Supervision, Visualization, Writing – review & editing. JO: Resources, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the University of Wisconsin-Madison GHI One Health Colombia, the Universidad Nacional de Colombia (Medellin), and the Abbott Pandemic Defense Coalition.

References

Alfonso-Morales, A., Rios, L., Martínez-Pérez, O., Dolz, R., Valle, R., Perera, C. L., et al. (2015). Evaluation of a phylogenetic marker based on genomic segment B of infectious bursal disease virus: facilitating a feasible incorporation of this segment to the molecular epidemiology studies for this viral agent. *PLoS One* 10:e0125853. doi: 10.1371/journal.pone.0125853

Anisimova, M., and Yang, Z. (2007). Multiple hypothesis testing to detect lineages under positive selection that affects only a few sites. *Mol. Biol. Evol.* 24, 1219–1228. doi: 10.1093/molbev/msm042

Averhoff, F., Berg, M., Rodgers, M., Osmanov, S., Luo, X., Anderson, M., et al. (2022). The Abbott pandemic defense coalition: a unique multisector approach adds to global pandemic preparedness efforts. *Int. J. Infect. Dis.* 117, 356–360. doi: 10.1016/j.ijid.2022.02.001

Acknowledgments

We thank the collaborating staff from the healthcare institutions (Hospital San Rafael de Leticia y Fundación Clínica de Leticia) for their assistance and coordination of fieldwork activities in this study. We also thank the One Health Genomic Laboratory staff at the Universidad Nacional for their assistance during laboratory work. Thanks to Fundacion Sofia Perez de Soto and Fundacion Fraternidad Medellin for supporting postgraduate students involved in this work.

Conflict of interest

LJP, MGB and GAC are Abbott employees and shareholders. JO is a single owner of Vaccigen, LLC. JO and JPHO are employees and shareholders of VaxThera.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The authors declare that no Gen AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2025.1548556/ full#supplementary-material

Berg, M. G., Olivo, A., Forberg, K., Harris, B. J., Yamaguchi, J., Shirazi, R., et al. (2020). Advanced molecular surveillance approaches for characterization of blood borne hepatitis viruses. *PLoS One* 15:e0236046. doi: 10.1371/journal.pone. 0236046

Bottieau, E., and Yansouni, C. P. (2018). Fever in the tropics: the ultimate clinical challenge? *Clin. Microbiol. Infect.* 24, 806–807. doi: 10.1016/j.cmi.2018.06.018

Ayres, D. L., Cummings, M. P., Baele, G., Darling, A. E., Lewis, P. O., Swofford, D. L., et al. (2019). BEAGLE 3: improved performance, scaling, and usability for a high-performance computing library for statistical phylogenetics. *Syst. Biol.* 68, 1052–1061. doi: 10.1093/sysbio/syz020

Cardoso, J. C., de Almeida, M. A. B., dos Santos, E., da Fonseca, D. F., Sallum, M. A. M., Noll, C. A., et al. (2010). Yellow fever virus in Haemagogus leucocelaenus and *Aedes serratus* mosquitoes, southern Brazil, 2008. *Emerg. Infect. Dis.* 16, 1918–1924. doi: 10.3201/eid1612.100608

Chen, H., Tang, M., Yao, L., Zhang, D., Zhang, Y., Zhao, Y., et al. (2023). Early application of metagenomics next-generation sequencing may significantly reduce unnecessary consumption of antibiotics in patients with fever of unknown origin. *BMC Infect. Dis.* 23:478. doi: 10.1186/s12879-023-08417-3

Ciuoderis, K. A., Berg, M. G., Perez, L. J., Hadji, A., Perez-Restrepo, L. S., Aristizabal, L. C., et al. (2022). Oropouche virus as an emerging cause of acute febrile illness in Colombia. *Emerg. Microbes Infect.* 11, 2645–2657. doi: 10.1080/22221751. 2022.2136536

Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., et al. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eur. Secur.* 25. doi: 10.2807/1560-7917.ES.2020.25.3.2000045

Coronado, L., Rios, L., Frías, M. T., Amarán, L., Naranjo, P., Percedo, M. I., et al. (2019). Positive selection pressure on E2 protein of classical swine fever virus drives variations in virulence, pathogenesis and antigenicity: implication for epidemiological surveillance in endemic areas. *Transbound. Emerg. Dis.* 66, 2362–2382. doi: 10.1111/tbed.13293

de Oliveira, F. P., Stoffella-Dutra, A. G., Barbosa Costa, G., Silva de Oliveira, J., Dourado Amaral, C., Duarte Santos, J., et al. (2020). Re-emergence of yellow fever in Brazil during 2016-2019: challenges, lessons learned, and perspectives. *Viruses* 12:1233. doi: 10.3390/v12111233

de-Paris, F., Beck, C., ABMP, M., Paiva, R. M., da Silva Menezes, D., de Souza Nunes, L., et al. (2012). Optimization of one-step duplex real-time RT-PCR for detection of influenza and respiratory syncytial virus in nasopharyngeal aspirates. *J. Virol. Methods* 186, 189–192. doi: 10.1016/j.jviromet.2012.07.008

Dhanda, S. K., Vita, R., Ha, B., Grifoni, A., Peters, B., and Sette, A. (2018). Immunome browser: a tool to aggregate and visualize complex and heterogeneous epitopes in reference proteins. *Bioinformatics* 34, 3931–3933. doi: 10.1093/bioinformatics/bty463

Drummond, A. J., and Rambaut, A. (2007). BEAST: Bayesian evolutionary analysis by sampling trees. *BMC Evol. Biol.* 7:214. doi: 10.1186/1471-2148-7-214

Faria, N. R., Kraemer, M. U. G., Hill, S. C., Goes de Jesus, J., Aguiar, R. S., FCM, I., et al. (2018). Genomic and epidemiological monitoring of yellow fever virus transmission potential. *Science* 361, 894–899. doi: 10.1126/science.aat7115

Feikin, D. R., Olack, B., Bigogo, G. M., Audi, A., Cosmas, L., Aura, B., et al. (2011). The burden of common infectious disease syndromes at the clinic and household level from population-based surveillance in rural and urban Kenya. *PLoS One* 6:e16085. doi: 10.1371/journal.pone.0016085

Frierson, J. G. (2010). The yellow fever vaccine: a history. Yale J. Biol. Med. 83, 77-85

Furtado, N. D., Raphael, L. M., Ribeiro, I. P., de Mello, I. S., Fernandes, D. R., Gómez, M. M., et al. (2022). Biological characterization of yellow fever viruses isolated from non-human primates in Brazil with distinct genomic landscapes. *Front. Microbiol.* 13:757084. doi: 10.3389/fmicb.2022.757084

Galbraith, S. E., and Barrett, A. D. T. (2009). "Chapter 40 - yellow fever" in Vaccines for biodefense and emerging and neglected diseases. eds. A. D. T. Barrett and L. R. Stanberry (London: Academic Press), 753–785.

Gardner, C. L., and Ryman, K. D. (2010). Yellow fever: a reemerging threat. *Clin. Lab. Med.* 30, 237–260. doi: 10.1016/j.cll.2010.01.001

Giovanetti, M., Pereira, L. A., Santiago, G. A., Fonseca, V., Mendoza, M. P. G., de Oliveira, C., et al. (2022). Emergence of dengue virus serotype 2 cosmopolitan genotype, Brazil. *Emerg Infect Dis* 28, 1725–1727. doi: 10.3201/eid2808.220550

Giovanetti, M., Pinotti, F., Zanluca, C., Fonseca, V., Nakase, T., Koishi, A. C., et al. (2023). Genomic epidemiology unveils the dynamics and spatial corridor behind the yellow fever virus outbreak in southern Brazil. *Sci. Adv.* 9:eadg9204. doi: 10.1126/sciadv.adg9204

Hill, V., and Baele, G. (2019). Bayesian estimation of past population dynamics in BEAST 1.10 using the skygrid coalescent model. *Mol. Biol. Evol.* 36, 2620–2628. doi: 10.1093/molbev/msz172

Instituto Nacional de S. Informe de Evento. Fiebre Amarilla. (2023).

Instituto Nacional de S (2023). Boletín epidemiológico semanal 08 de 2023, -34.

Jerome, H., Taylor, C., Sreenu, V. B., Klymenko, T., Filipe, A. D. S., Jackson, C., et al. (2019). Metagenomic next-generation sequencing aids the diagnosis of viral infections in febrile returning travellers. *J. Infect.* 79, 383–388. doi: 10.1016/j.jinf.2019.08.003

Juan-Giner, A., and Hombach, J. (2024). The life-long protective immunity of yellow fever vaccination: time to review? *Lancet Glob. Health* 12, e352–e353. doi: 10.1016/s2214-109x(23)00594-6

Kalantar, K. L., Carvalho, T., de Bourcy, C. F. A., Dimitrov, B., Dingle, G., Egger, R., et al. (2020). IDseq-an open source cloud-based pipeline and analysis service for metagenomic pathogen detection and monitoring. *Gigascience* 9. doi: 10.1093/gigascience/giaa111

Kamau, E., Alemayehu, S., Feghali, K. C., Saunders, D., and Ockenhouse, C. F. (2013). Multiplex qPCR for detection and absolute quantification of malaria. *PLoS One* 8:e71539. doi: 10.1371/JOURNAL.PONE.0071539 Kieffer, A., Hoestlandt, C., Gil-Rojas, Y., Broban, A., Castañeda-Cardona, C., and Rosselli, D. (2019). The public health benefits and economic value of routine yellow fever vaccination in Colombia. *Value Health Reg. Issues* 20, 60–65. doi: 10.1016/j.vhri. 2019.01.004

Lemey, P., Hong, S. L., Hill, V., Baele, G., Poletto, C., Colizza, V., et al. (2020). Accommodating individual travel history and unsampled diversity in Bayesian phylogeographic inference of SARS-CoV-2. *Nat. Commun.* 11:5110. doi: 10.1038/s41467-020-18877-9

Lemey, P., Ruktanonchai, N., Hong, S. L., Colizza, V., Poletto, C., Van den Broeck, F., et al. (2021). Untangling introductions and persistence in COVID-19 resurgence in Europe. *Nature* 595, 713–717. doi: 10.1038/s41586-021-03754-2

Li, Y. (2022). Molecular epidemiology of yellow fever virus in Africa: a perspective of the phylogeographic split between east/central African and west African lineages. *Acta Trop.* 225:106199. doi: 10.1016/j.actatropica.2021.106199

Malik, S., Pandey, I., Kishore, S., Sundarrajan, T., Nargund, S. L., Ghosh, A., et al. (2023). Yellow fever virus, a mosquito-borne flavivirus posing high public health concerns and imminent threats to travellers - an update. *Int. J. Surg.* 109, 134–137. doi: 10.1097/JS9.00000000000086

Moreira, J., Bressan, C. S., Brasil, P., and Siqueira, A. M. (2018). Epidemiology of acute febrile illness in Latin America. *Clin. Microbiol. Infect.* 24, 827–835. doi: 10.1016/j.cmi.2018.05.001

Nguyen, L.-T., Schmidt, H. A., von Haeseler, A., and Minh, B. Q. (2015). IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol. Biol. Evol.* 32, 268–274. doi: 10.1093/molbev/msu300

Nunes, M. R. T., Palacios, G., Nunes, K. N. B., Casseb, S. M. M., Martins, L. C., Quaresma, J. A. S., et al. (2011). Evaluation of two molecular methods for the detection of yellow fever virus genome. J. Virol. Methods 174, 29–34. doi: 10.1016/J.JVIROMET.2011.02.025

Orf, G. S., Perez, L. J., Meyer, T. V., Luk, K. C., Forberg, K., Rodgers, M. A., et al. (2023). Purifying selection decreases the potential for Bangui orthobunyavirus outbreaks in humans. *Virus Evolution* 9:vead018. doi: 10.1093/ve/vead018

Pan American Health Organization (2023). Country profile of yellow fever. Colombia. Available at: https://www.paho.org/en/documents/country-profile-yellow-fever-colombia

Paules, C. I., and Fauci, A. S. (2017). Yellow fever - once again on the radar screen in the Americas. N. Engl. J. Med. 376, 1397–1399. doi: 10.1056/NEJMp1702172

Peeling, R. W. W., and Fongwen, N. (2022). Solving the enigma of acute febrile illness. *Lancet Infect. Dis.* 22, 1261–1262. doi: 10.1016/S1473-3099(22)00313-9

Perez, L. J., Forberg, K., Cloherty, G. A., and Berg, M. G. (2023). Temporal and coevolutionary analyses reveal the events driving the emergence and circulation of human mamastroviruses. *Emerg. Microbes Infect.* 12:2217942. doi: 10.1080/22221751.2023.2217942

Perez, L. J., Orf, G. S., Berg, M. G., Rodgers, M. A., Meyer, T. V., Mohaimani, A., et al. (2022). The early SARS-CoV-2 epidemic in Senegal was driven by the local emergence of B.1.416 and the introduction of B.1.1.420 from Europe. *Virus Evol.* 8:veac025. doi: 10.1093/ve/veac025

Prasad, N., Murdoch, D. R., Reyburn, H., and Crump, J. A. (2015). Etiology of severe febrile illness in low- and middle-income countries: a systematic review. *PLoS One* 10:e0127962. doi: 10.1371/journal.pone.0127962

Rambaut, A., Drummond, A. J., Xie, D., Baele, G., and Suchard, M. A. (2018). Posterior summarization in Bayesian phylogenetics using tracer 1.7. *Syst. Biol.* 67, 901–904. doi: 10.1093/sysbio/syy032

Rodrigue, J.-P. (2020). *The geography of transport systems (5th ed.)*. Routledge. Available at: https://www.taylorfrancis.com/books/mono/10.4324/9780429346323/geography-transport-systems-jean-paul-rodrigue

Rosenstein, M. D., de Visser, A. W., Visser, L. G., and Roukens, A. H. E. (2021). Longterm immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: a 10-year follow-up study. *J. Travel Med.* 28. doi: 10.1093/jtm/taab126

Rozewicki, J., Li, S., Amada, K. M., Standley, D. M., and Katoh, K. (2019). MAFFT-DASH: integrated protein sequence and structural alignment. *Nucleic Acids Res.* 47, W5–W10. doi: 10.1093/nar/gkz342

Ryan, K. (2024). Fever of unknown origin. Med. Clin. North Am. 108, 79-92. doi: 10.1016/j.mcna.2023.05.016

Shet, A., Carr, K., Danovaro-Holliday, M. C., Sodha, S. V., Prosperi, C., Wunderlich, J., et al. (2022). Impact of the SARS-CoV-2 pandemic on routine immunisation services: evidence of disruption and recovery from 170 countries and territories. *Lancet Glob. Health* 10, e186–e194. doi: 10.1016/S2214-109X(21)00512-X

Staples, J. E., and Monath, T. P. (2008). Yellow fever: 100 years of discovery. *JAMA* 300, 960–962. doi: 10.1001/jama.300.8.960

Suchard, M. A., Lemey, P., Baele, G., Ayres, D. L., Drummond, A. J., and Rambaut, A. (2018). Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10. *Virus Evol* 4:vey 016. doi: 10.1093/ve/vey016

Waggoner, J. J., Gresh, L., Mohamed-Hadley, A., Ballesteros, G., Davila, M. J. V., Tellez, Y., et al. (2016). Single-reaction multiplex reverse transcription PCR for detection of Zika, chikungunya, and dengue viruses. *Emerg. Infect. Dis.* 22, 1295–1297. doi: 10.3201/EID2207.160326

Wangdi, K., Kasturiaratchi, K., Nery, S. V., Lau, C. L., Gray, D. J., and Clements, A. C. A. (2019). Diversity of infectious aetiologies of acute undifferentiated febrile illnesses in south and Southeast Asia: a systematic review. *BMC Infect. Dis.* 19:577. doi: 10.1186/s12879-019-4185-y Weaver, S., Shank, S. D., Spielman, S. J., Li, M., Muse, S. V., and Kosakovsky Pond, S. L. (2018). Datamonkey 2.0: a modern web application for characterizing selective and other evolutionary processes. *Mol. Biol. Evol.* 35, 773–777. doi: 10.1093/molbev/msx335

World Health Organization. Immunization coverage. (2023a). Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON431.

World Health Organization. (2023b). Disease Outbreak News; Yellow fever in East, West, and Central Africa. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON431

Wright, W. F., Simner, P. J., Carroll, K. C., and Auwaerter, P. G. (2022). Progress report: next-generation sequencing, multiplex polymerase chain reaction, and broad-range

molecular assays as diagnostic tools for fever of unknown origin investigations in adults. *Clin. Infect. Dis.* 74, 924–932. doi: 10.1093/cid/ciab155

Yang, Z. (2007). PAML 4: phylogenetic analysis by maximum likelihood. *Mol. Biol. Evol.* 24, 1586–1591. doi: 10.1093/molbev/msm088

Yu, X., and Cheng, G. (2022). Adaptive evolution as a driving force of the emergence and re-emergence of mosquito-borne viral diseases. *Viruses* 14:435. doi: 10.3390/v14020435

Yu, G., Smith, D. K., Zhu, H., Guan, Y., and Lam, T. T.-Y. (2017). Ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data. *Methods Ecol. Evol.* 8, 28–36. doi: 10.1111/2041-210x.12628